Novo Nordisk’s OZEMPIC Approval Heat Up the Chronic Kidney Disease Therapeutic Market | DelveInsight
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
Novo Nordisk Sues Singapore-Based KBP Biosciences Over Alleged Data Misrepresentation In $1.3 Billion Hypertension Drug Deal, Seeks Damages
Novo Nordisk sues KBP Biosciences, seeking $830 million in damages over Ocedurenone, alleging data misrepresentation that led ...
pharmaphorum10h
When licensing deals go bad - Novo sues KBP Bio for $830m
A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...
Medical News Today9h
Drug for diabetes and kidney disease may also lower heart attack, stroke risks
An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help lower their stroke and heart attack risk, a new study has found.
Innovative technology enhances cellular and molecular insights into kidney lesions
Researchers have demonstrated the feasibility of a morphological-based approach to interpreting spatial transcriptomic (ST) data, helping to improve understanding of the lesions that occur in chronic ...
Drug Store News7h
Generic drug suppliers weigh in on predictable, unpredictable category impact
Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that ...
Drug Store News7h
Unsure and Uncertain
In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...